Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New bone graft material could improve spine surgery outcomes

NCT ID NCT03853356

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 11, 2026 · Updated 2 times

Summary

This study is testing a material called Orthoss®, made from granules, to help bones in the spine fuse together after surgery. The trial includes 65 adults with lower back problems like slipped discs or narrowing of the spine canal. Doctors will check if the bones fuse properly and if patients feel better over 24 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Orthoss® granules (bone graft extender)
What this could lead to
If successful, Orthoss® could provide a safe and effective option to help spine bones fuse together after surgery, potentially reducing the need for additional bone grafts.
What could go wrong
This is a small, early-stage study (65 people) with no control group, so results may not apply broadly. The main risk is that the fusion may not occur as expected, requiring further surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 65 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2019

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Orthoss® mixed with local bone and pedicle bone marrow aspirate in lumbar spondylodesis by using transforaminal lumbar interbody fusion (TLIF) and posterior lumbar interbody fusion (PLIF) techniques in the 1-2 levels.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The patient (male or female) must be 18 years or older * The patient must be a candidate diagnosed with either degenerative disc disease including 1-2 level (L4-L5 and/or L5-S1) or dysplasic spondylolisthesis (degree 1 or 2) or lumbar stenosis * If the patient is of child-bearing potential, the patient confirms not to be pregnant * The patient is able to comply with the clinical investigation-related procedures such as attending all follow-up procedures * The patient is able to fully understand the nature of the proposed surgery and is able to provide a signed informed consent including the use of the anonymized data for scientific publication * The patient will not participate in another clinical investigation during this clinical investigation Exclusion Criteria: * General contraindications for surgical treatment are present * The patient has a history of malignancy, radiotherapy, or chemotherapy for malignancy within the past five years * The patient is currently being treated with radiation, chemotherapy, immunosuppression or steroid therapy dose equivalent of more than 5mg prednisolon * The patient is pregnant or nursing * Women of childbearing age who are not using a highly effective method of birth control * The patient has acute or chronic infection at the surgical site * The patient has a known allergy to bovine bone material * The patient has a medical history of alcohol or drug abuse within the last year prior to the screening examination * Vulnerable population * Patient is currently participating, or has participated in another clinical investigation within 6 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lumbar disc degeneration are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Klinikum Magdeburg gGmbH

    Magdeburg, Germany

  • Universitätsklinikum Augsburg - Neurochirurgische Klinik und Poliklinik

    Augsburg, Germany

  • Universitätsklinikum Düsseldorf

    Düsseldorf, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.